Block JNK at the dock

A team of U.S. researchers has described a new mitogen-activated protein kinase 8 (JNK; MAPK8) inhibitor that targets JNK's substrate docking site-instead of its ATP binding site-to treat type 2 diabetes.1 The targeting strategy should be applicable to other diseases in which JNK is implicated and to the inhibition of other protein kinases.

The research team from the Burnham Institute for Medical Research, the University of California, San Diego and Invitrogen Corp.'s Invitrogen Discovery Services unit in Wisconsin was led by Maurizio Pellecchia, professor of infectious diseases at Burnham.

"Our goal is to provide chemical probes that provide information about the JNK docking site and its requirements," Pellecchia told SciBX. "This is a basic science approach with a clear translational component. The compounds themselves are free for research purposes."

JNK bonds

The three c-Jun N-terminal kinases (JNK1; JNK2; JNK3) are members of the mitogen-activated protein kinase (MAPK) family and are activated by cytokines or

Read the full 1508 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE